Neurocrine Biosciences Inc vs Paychex, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $152.14 (market cap $16.46B), while Paychex, Inc. trades at $121.11 (market cap $43.14B). The key difference: Paychex, Inc. is far larger — about 2.6× Neurocrine Biosciences Inc's market cap, and Paychex, Inc. pays a 3.92% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | PAYX | |
|---|---|---|
Market Cap | $16.46B | $43.14B |
Sector | Health | Industrials |
52-Week High | $185.50 | $140.81 |
52-Week Low | $123.10 | $85.57 |
Enterprise Value | $16.48B | $46.63B |
Dividend Yield | — | 3.92% |
Trailing returns across standard periods
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →